Day One Biopharmaceuticals, Inc. (DAWN) Financial Statements (2025 and earlier)

Company Profile

Business Address 2000 SIERRA POINT PARKWAY, SUITE 501
BRISBANE, CA 94005
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments366,347342,269284,309
Cash and cash equivalent230,78485,262284,309
Short-term investments135,563257,007 
Receivables   
Inventory, net of allowances, customer advances and progress billings   
Inventory   
Prepaid expense3,2702,5983,114
Other undisclosed current assets5,6573,0071,945
Total current assets:375,274347,874289,368
Noncurrent Assets
Operating lease, right-of-use asset352699227
Property, plant and equipment2082057
Intangible assets, net (including goodwill)   
Intangible assets, net (excluding goodwill)   
Deposits noncurrent assets   71
Other undisclosed noncurrent assets21446998
Total noncurrent assets:7741,188453
TOTAL ASSETS:376,048349,062289,821
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:26,52416,2108,453
Accounts payable2,5762601,744
Accrued liabilities4,71615,9506,709
Other undisclosed accounts payable and accrued liabilities19,232  
Deferred revenue   
Other undisclosed current liabilities2,984405204
Total current liabilities:29,50816,6158,657
Noncurrent Liabilities
Long-term debt and lease obligation:   16
Liabilities, other than long-term debt 408 
Deferred revenue   
Other liabilities   
Operating lease, liability 40816
Other undisclosed noncurrent liabilities   (16)
Total noncurrent liabilities: 40816
Total liabilities:29,50817,0238,673
Equity
Equity, attributable to parent, including:346,540332,039281,148
Common stock97 
Additional paid in capital805,107601,771408,629
Accumulated other comprehensive income (loss)9(71) 
Accumulated deficit(458,585)(269,668)(127,487)
Other undisclosed equity, attributable to parent   6
Total equity:346,540332,039281,148
TOTAL LIABILITIES AND EQUITY:376,048349,062289,821

Income Statement (P&L) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues   
Gross profit:   
Operating expenses(206,064)(146,909)(72,743)
Operating loss:(206,064)(146,909)(72,743)
Nonoperating income (expense)17,147(18)(15)
Investment income, nonoperating17,187  
Other nonoperating income (expense)(40)(18)(15)
Loss from continuing operations before income taxes:(188,917)(146,927)(72,758)
Income tax expense   
Loss from continuing operations:(188,917)(146,927)(72,758)
Loss before gain (loss) on sale of properties:(72,758)
Other undisclosed net income  4,7464
Net loss:(188,917)(142,181)(72,754)
Net income attributable to noncontrolling interest   2,109
Net loss available to common stockholders, diluted:(188,917)(142,181)(70,645)

Comprehensive Income ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net loss:(188,917)(142,181)(72,754)
Comprehensive loss:(188,917)(142,181)(72,754)
Comprehensive income, net of tax, attributable to noncontrolling interest   2,109
Other undisclosed comprehensive income (loss), net of tax, attributable to parent80(71) 
Comprehensive loss, net of tax, attributable to parent:(188,837)(142,252)(70,645)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: